Mylonib 15mg 60 Tablets

Buy Mylonib 15mg at PakMeds | Ruxolitinib for Myelofibrosis

Mylonib 15mg is an oral targeted therapy for adults with myelofibrosis and polycythemia vera. Each tablet contains Ruxolitinib, a JAK inhibitor that calms an overactive bone marrow signaling pathway. Order Mylonib from PakMeds for secure packaging and reliable delivery across all major cities in Pakistan.

Mylonib Ingredients and Usage

Mylonib contains Ruxolitinib, a JAK1 and JAK2 inhibitor that targets overactive signaling inside the bone marrow. JAK (Janus kinase) enzymes relay the growth signals that control blood cell production and immune activity. Doctors prescribe Mylonib for adults with myelofibrosis, a disorder where scar tissue replaces healthy marrow.

Mylonib also treats polycythemia vera in adults who cannot tolerate or no longer respond to hydroxyurea. Specialists set the dose by platelet count, often starting at 15mg twice daily. Patients swallow one tablet twice daily, with or without food, exactly as the haematologist directs.

How Does Mylonib Work?

Mylonib works by blocking JAK1 and JAK2, two enzymes in the JAK-STAT signaling pathway inside blood cells. In myelofibrosis and polycythemia vera, mutations such as JAK2 V617F keep this pathway switched on permanently. Ruxolitinib quiets the pathway, lowering inflammatory cytokines and slowing the overproduction of blood cells.

Mylonib reduces an enlarged spleen and eases symptoms such as night sweats, fatigue, and weight loss. By dampening JAK signaling, Ruxolitinib lowers phosphorylation of STAT proteins that drive abnormal cell growth. In phase 3 trials, Ruxolitinib shrank spleen volume by 35% or more in many patients at 24 weeks.

Mylonib Side Effects

Mylonib commonly lowers blood counts and can raise infection risk, so patients need regular blood monitoring. Report fever, unusual bruising, or any sign of infection to your haematology team without delay.

• Low platelets (thrombocytopenia)

• Anemia (low red blood cells)

• Low white cells (neutropenia)

• Easy bruising

• Dizziness

• Headache

• Raised liver enzymes (ALT and AST)

• Raised cholesterol

• Weight gain

• Diarrhea

• Higher risk of infections, including shingles and urinary infections

• Fatigue and general weakness

Warnings

• Mylonib lowers platelets, red cells, and neutrophils. Doctors check a complete blood count before treatment and at regular intervals during therapy.

• Serious infections can occur. Do not start Mylonib during an active serious infection, and your doctor will screen for tuberculosis, hepatitis B, and shingles.

• Never stop Mylonib suddenly, since abrupt withdrawal can trigger a severe return of symptoms. Your doctor will taper the dose if treatment must end.

• JAK inhibitors carry a risk of major cardiac events, blood clots, and second cancers. Discuss your heart and cancer history before starting.

• Nonmelanoma skin cancers have occurred with Ruxolitinib. Doctors examine the skin regularly throughout treatment.

• Strong CYP3A4 inhibitors such as ketoconazole and fluconazole raise Ruxolitinib blood levels. Your doctor will lower the Mylonib dose if you take them.

• Liver or kidney impairment may require a reduced dose, so tell your doctor about any organ problems.

• Mylonib may harm an unborn baby. Use effective contraception during therapy and avoid breastfeeding while taking Mylonib.

• Tell your doctor about any history of blood clots, heart disease, skin cancer, or chronic infection before starting Mylonib.

Mylonib Storage Conditions

Store Mylonib 15mg tablets at room temperature between 20°C and 25°C in a cool, dry place away from direct light. Keep the tablets in their original closed bottle to protect Ruxolitinib from moisture and excess heat, which degrade the active ingredient. Always store the bottle safely out of reach of children and household pets.